136 related articles for article (PubMed ID: 7696962)
21. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
22. Effects of macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor on osteoclastic differentiation of hematopoietic progenitor cells.
Liggett W; Shevde N; Anklesaria P; Sohoni S; Greenberger J; Glowacki J
Stem Cells; 1993 Sep; 11(5):398-411. PubMed ID: 8241951
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know.
Shi Y; Liu CH; Roberts AI; Das J; Xu G; Ren G; Zhang Y; Zhang L; Yuan ZR; Tan HS; Das G; Devadas S
Cell Res; 2006 Feb; 16(2):126-33. PubMed ID: 16474424
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte-macrophage colony stimulating factor and interleukin 3: target cells and kinetics of response in vivo.
Aglietta M; Pasquino P; Sanavio F; Stacchini A; Severino A; Fubini L; Morelli S; Volta C; Monteverde A; Piacibello W
Stem Cells; 1993 Jul; 11 Suppl 2():83-7. PubMed ID: 8401260
[TBL] [Abstract][Full Text] [Related]
25. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal.
van Os R; Robinson S; Sheridan T; Mauch PM
Stem Cells; 2000; 18(2):120-7. PubMed ID: 10742384
[TBL] [Abstract][Full Text] [Related]
27. Clinical applications of human granulocyte-macrophage colony-stimulating factor.
Sakamoto KM; Gasson JC
Int J Cell Cloning; 1991 Nov; 9(6):531-41. PubMed ID: 1770227
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
29. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
[TBL] [Abstract][Full Text] [Related]
30. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
31. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
34. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
Vadhan-Raj S
Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
[TBL] [Abstract][Full Text] [Related]
35. Reactive oxygen species mediate stem cell factor synergy with granulocyte/macrophage colony-stimulating factor in a subpopulation of primitive murine hematopoietic progenitor cells.
Pyatt DW; Stillman WS; Irons RD
Mol Pharmacol; 1996 Jun; 49(6):1097-1103. PubMed ID: 8649349
[TBL] [Abstract][Full Text] [Related]
36. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients.
Root RK; Dale DC
J Infect Dis; 1999 Mar; 179 Suppl 2():S342-52. PubMed ID: 10081506
[TBL] [Abstract][Full Text] [Related]
38. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia.
Lee J; Kim Y; Lim J; Kim M; Han K
Ann Clin Lab Sci; 2008; 38(4):331-7. PubMed ID: 18988925
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte-macrophage colony-stimulating factor with dose-intensified treatment of cancer.
Clark DA; Neidhart JA
Semin Hematol; 1992 Oct; 29(4 Suppl 3):27-32. PubMed ID: 1492231
[TBL] [Abstract][Full Text] [Related]
40. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
Clive KS; Tyler JA; Clifton GT; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2010 May; 9(5):519-25. PubMed ID: 20450326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
